/PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy...
The company gave a presentation regarding its lead therapy to treat solid tumors.
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?